FATE Fate Therapeutics (FATE) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001434316
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
90
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $292.5K priced
What the filings say about FATE
Insiders, 180 days
-$306.0K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$203.5K
2 notices
Fate Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, FATE THERAPEUTICS INC insiders sold a net $306.0K of stock across 141 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on May 20, 2026.
- The trade is 7.4% of the 591,815 shares held after it.
- 1 other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Valamehr Bahram sold about $108.1K of FATE on Aug 4, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 90 funds added in the latest 13F quarter.Context
- 31 earlier Form 4 trades (code P or S) here by this insider (31 sales), the last on May 20, 2026.
- The trade is 6.6% of the 589,355 shares held after it.
- 1 other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks TAHL CINDY sold about $95.4K of FATE on Aug 4, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 90 funds added in the latest 13F quarter.Context
- 30 earlier Form 4 trades (code P or S) here by this insider (30 sales), the last on Jan 9, 2026.
- The trade is 4.1% of the 628,155 shares held after it.
- 1 other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks TAHL CINDY sold about $48.1K of FATE on May 20, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 90 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Jan 9, 2026.
- The trade is 4.6% of the 635,762 shares held after it.
- 1 other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Valamehr Bahram sold about $54.4K of FATE on May 20, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 90 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Aug 4, 2025.
- The trade is 2.7% of the 387,081 shares held after it.
- 1 other insider sold within 30 days.
- 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks TAHL CINDY sold about $11.2K of FATE on Jan 9, 2026; 1 other insider sold within 30 days and 90 funds added in the latest 13F quarter.141 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$306.0K over 180 days
-$203.5K over 90 days
below 51% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
90 funds bought in last quarter
more than 64% of Pharma & Biotech
Revenue
-51.2% year over year
below 81% of Pharma & Biotech
Margin
-2051.1% net margin
below 92% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.2% of the float short (float per yahoo 2026-10-26) · 5.3 days to cover · settled 2026-09-30
more than 68% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FATE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+41.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FATE: institutional holders (13F)
13F holdings, latest reported quarter
12,872,946 sh
$34.8M
7,298,895 sh
$19.7M
4,545,893 sh
$12.3M
4,445,536 sh
$12.0M
3,837,229 sh
$10.4M
Congress trades in FATE
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
FATE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Valamehr Bahram
Filed 2026-08-04
$108.1K
TAHL CINDY
Filed 2026-08-04
$95.4K
FATE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$147.4K position · as of 2026-05-31
0.8%
BRUCE FUND
$2.7M position · as of 2026-06-30
0.7%
Ultra-Small Company Market Fund
$499.5K position · as of 2026-06-30
0.3%
AQR Small Cap Multi-Style Fund
$692.2K position · as of 2026-06-30
0.2%
VANGUARD MARKET NEUTRAL FUND
$832.7K position · as of 2026-06-30
0.1%
AVIP BlackRock Advantage Small Cap Growth Portfolio
$121.2K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
18 registered trials, 6 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
14
Phase 1
4 active
1
Phase 2
1 active
1
Not applicable
0 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · J. Scott Wolchko
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$8.1M
-$12.4M
$3.2M
-83%
n/a
2021
$11.7M
-$11.6M
$6.8M
-36%
n/a
2020
$5.6M
$78.6M
$3.3M
n/a
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $306.0K sold by insiders over 180 days, 90 funds added last quarter, $203.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
FATE financials
Revenue growth
-51.2%
XBRL, annual
Net margin
-2051.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM FATE
| FY Dec 2025 | $6.6M |
| FY Dec 2024 | $13.6M |
| FY Dec 2023 | $63.5M |
| FY Dec 2022 | $96.3M |
| FY Dec 2021 | $55.8M |
| Jun 2026 | $2.1M |
| Mar 2026 | $1.3M |
| Dec 2025 | $1.4M |
| Sep 2025 | $1.7M |
| Jun 2025 | $1.9M |
| Mar 2025 | $1.6M |
| Dec 2024 | $1.9M |
| Sep 2024 | $3.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-1,941%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM FATE
| FY Dec 2025 | -2,051% |
| FY Dec 2024 | -1,366% |
| FY Dec 2023 | -253.3% |
| FY Dec 2022 | -292.5% |
| FY Dec 2021 | -379.9% |
| Jun 2026 | -1,449% |
| Mar 2026 | -2,403% |
| Dec 2025 | -2,365% |
| Sep 2025 | -1,852% |
| Jun 2025 | -1,787% |
| Mar 2025 | -2,309% |
| Dec 2024 | -2,804% |
| Sep 2024 | -1,551% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$105.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FATE
| FY Dec 2025 | -$112.0M |
| FY Dec 2024 | -$123.6M |
| FY Dec 2023 | -$138.4M |
| FY Dec 2022 | -$283.8M |
| FY Dec 2021 | -$213.6M |
| Jun 2026 | -$23.5M |
| Mar 2026 | -$31.1M |
| Dec 2025 | -$24.5M |
| Sep 2025 | -$26.6M |
| Jun 2025 | -$25.9M |
| Mar 2025 | -$35.0M |
| Dec 2024 | -$27.9M |
| Sep 2024 | -$29.9M |
At each fiscal year end
Single quarter
Debt to equity
0.15x
long-term 2019-06-30 (85 months older than the period end) plus current 2019-09-30 (82 months older than the period end); equity 2026-06-30
Debt to equity FATE
| FY Dec 2025 | 0.11x |
| FY Dec 2024 | 0.07x |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | 0.05x |
| FY Dec 2021 | 0.03x |
| Jun 2026 | 0.15x |
| Mar 2026 | 0.13x |
| Dec 2025 | 0.11x |
| Sep 2025 | 0.10x |
| Jun 2025 | 0.09x |
| Mar 2025 | 0.08x |
| Dec 2024 | 0.07x |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-4.35x
TTM operating cash flow over long-term 2019-06-30 (85 months older than the period end) plus current 2019-09-30 (82 months older than the period end)
Cash flow to debt FATE
| FY Dec 2025 | -4.53x |
| FY Dec 2024 | -5.25x |
| FY Dec 2023 | -5.65x |
| FY Dec 2022 | -10.61x |
| FY Dec 2021 | -6.96x |
| Jun 2026 | -4.35x |
| Mar 2026 | -4.41x |
| Dec 2025 | -4.53x |
| Sep 2025 | -4.72x |
| Jun 2025 | -4.94x |
| Mar 2025 | -5.27x |
| Dec 2024 | -5.25x |
| Sep 2024 | -5.63x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-60.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FATE
| FY Dec 2025 | -51.8% |
| FY Dec 2024 | -54.2% |
| FY Dec 2023 | -37.8% |
| FY Dec 2022 | -48.5% |
| FY Dec 2021 | -39.9% |
| Jun 2026 | -60.7% |
| Mar 2026 | -55.5% |
| Dec 2025 | -51.8% |
| Sep 2025 | -52.3% |
| Jun 2025 | -52.1% |
| Mar 2025 | -49.2% |
| Dec 2024 | -54.2% |
| Sep 2024 | -46.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-39.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FATE
| FY Dec 2025 | -35.9% |
| FY Dec 2024 | -39.3% |
| FY Dec 2023 | -26.6% |
| FY Dec 2022 | -34.6% |
| FY Dec 2021 | -27.5% |
| Jun 2026 | -39.9% |
| Mar 2026 | -38.0% |
| Dec 2025 | -35.9% |
| Sep 2025 | -37.2% |
| Jun 2025 | -38.1% |
| Mar 2025 | -36.3% |
| Dec 2024 | -39.3% |
| Sep 2024 | -34.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital FATE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-46.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FATE
| FY Dec 2025 | -43.1% |
| FY Dec 2024 | -48.4% |
| FY Dec 2023 | -36.0% |
| FY Dec 2022 | -43.1% |
| FY Dec 2021 | -31.5% |
| Jun 2026 | -46.8% |
| Mar 2026 | -44.6% |
| Dec 2025 | -43.1% |
| Sep 2025 | -45.2% |
| Jun 2025 | -46.0% |
| Mar 2025 | -44.8% |
| Dec 2024 | -48.4% |
| Sep 2024 | -41.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing FATE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$243.8M
market value at close 2026-10-23 on 2026-08-06 shares, plus long-term 2019-06-30 (85 months older than the period end) plus current 2019-09-30 (82 months older than the period end), minus cash 2026-06-30
Enterprise value FATE
| FY Dec 2025 | $89.8M |
| FY Dec 2024 | $175.3M |
| FY Dec 2023 | $350.3M |
| FY Dec 2022 | $942.5M |
| FY Dec 2021 | $5.5B |
| Jun 2026 | $305.7M |
| Mar 2026 | $123.3M |
| Dec 2025 | $89.8M |
| Sep 2025 | $128.1M |
| Jun 2025 | $110.5M |
| Mar 2025 | $69.0M |
| Dec 2024 | $175.3M |
| Sep 2024 | $384.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-41.8%
TTM free cash flow over market value at close 2026-10-23
FCF yield FATE
| FY Dec 2025 | -99.1% |
| FY Dec 2024 | -65.8% |
| FY Dec 2023 | -37.5% |
| FY Dec 2022 | -28.9% |
| FY Dec 2021 | -3.8% |
| Jun 2026 | -33.6% |
| Mar 2026 | -77.5% |
| Dec 2025 | -99.1% |
| Sep 2025 | -79.4% |
| Jun 2025 | -92.5% |
| Mar 2025 | -138.3% |
| Dec 2024 | -65.8% |
| Sep 2024 | -33.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing FATE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M |
| Operating income | -$147.7M | -$210.3M | -$190.5M | -$308.4M |
| Net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M |
| EPS (diluted) | -1.15 | -1.64 | -1.64 | -2.91 |
| Operating cash flow | -$106.1M | -$122.9M | -$132.3M | -$248.2M |
| Cash | $46.6M | $36.1M | $41.9M | $61.3M |
SEC XBRL, fiscal years, as known on 2026-10-27
FATE Stock Sonar score 6/7 axes
Find similar shapesCompareFATE ranks highest on institutional and government (64th percentile) and profitability (51st), and lowest on growth (19th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FATE filings, in plain words
Are Fate Therapeutics insiders buying or selling FATE?
In the 180 days to 2026-10-27, Fate Therapeutics insiders were net sellers, a net $306.0K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of FATE?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $203.5K of stock; the latest, by Valamehr Bahram, was filed 2026-08-04.
Read the full summary
In the 180 days to 2026-10-27, Fate Therapeutics insiders were net sellers of FATE, a net $306.0K across purchases and sales reported on Form 4 by 2 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $203.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
